Ginkgo Bioworks Holdings, Inc.
NYSE:DNABiotechnology
+$0.26 today
- Market cap
- $547.12M
- Beta
- 1.80
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$5.11
Volume 2.36M
Average 1.24M
DNA Net Income
Bottom-line profit after all expenses, interest, and taxes.
Ginkgo Bioworks Holdings, Inc.NYSE: DNA
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income remains negative
Q1 FY2026 net income was -$82.59M, compared with -$90.96M a year earlier. Trailing-twelve-month net income was -$304.39M.
Context
- Net income amounted to 183.8% of revenue in FY2025, down 57.1 pp from a year earlier.
- Net income grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 2 analysts of -$244.06M (+22.0%) for the fiscal year ending Dec 2026, a slowdown from the +42.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$82.59M-2.3% QoQ
- Last fiscal yearDec 2025
- -$312.76M+42.8% YoY
- LTMMar 2026
- -$304.39M+35.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +9.2% | +5.1% | -4.1 pp |
| 1 year | +42.8% | +22.0% | -20.9 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- (312.76M) USD
- Year-over-year change
- +42.8%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (312.76M) | +42.8% |
| FY2024 | 2024-12-31 | (547.03M) | +38.7% |
| FY2023 | 2023-12-31 | (892.87M) | +57.6% |
| FY2022 | 2022-12-31 | (2.1B) | -15.0% |
| FY2021 | 2021-12-31 | (1.83B) | — |
Net Income vs competitors
How DNA compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +35.5% is the 3rd highest of 10, against a peer median of -14.0%.
- Net income amounts to 215.4% of revenue for DNA, versus a peer median of 119.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | -$77.39M USD | +60.3% | — | 37.1% | |
| LTM Mar 2026 | -$120.53M USD | +28.0% | — | 151.1% | |
| LTM Mar 2026 | -€138.03M EUR | -71.7% | — | 88.3% | |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | -$145.1M USD | -80.3% | — | — |
| LTM Mar 2026 | -$145.24M USD | -14.0% | — | — | |
| LTM Sep 2026 | -$220.54M USD | +44.5% | — | 58.2% | |
| LTM Mar 2026 | -$221.3M USD | -374.9% | — | 247.5% | |
| LTM Mar 2026 | -$304.39M USD | +35.5% | — | 215.4% | |
| LTM Dec 2025 | -$314.85M USD | -37.9% | — | — | |
| LTM Mar 2026 | -$442.72M USD | +23.4% | — | 676.0% | |
| Peer median (excluding DNA) | — | -14.0% | — | 119.7% | |
Competitors are the stored peer set for DNA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 313.84M | 477.71M | 251.46M | 227.04M | 170.16M |
| Cost of Revenue | 129.69M | 204.22M | 54.01M | 38.55M | 31.52M |
| Gross Profit | 184.15M | 273.49M | 197.45M | 188.49M | 138.63M |
| Gross Margin | 58.7% | 57.3% | 78.5% | 83.0% | 81.5% |
| Research & Development | 1.15B | 1.05B | 580.62M | 424.06M | 243.77M |
| Selling, General & Admin | 862.95M | 1.43B | 385.03M | 246.16M | 183.29M |
| Operating Expenses | 2.01B | 2.48B | 1.06B | 748.25M | 453.91M |
| Depreciation & Amortization | 29.08M | 61.63M | 71.55M | 63.02M | 58.99M |
| EBITDA | (1.81B) | (2.06B) | (821.29M) | (484.39M) | (254.61M) |
| EBITDA Margin | -575.7% | -431.2% | -326.6% | -213.3% | -149.6% |
| Operating Income | (1.83B) | (2.21B) | (864.41M) | (559.76M) | (315.28M) |
| Operating Margin | -582.6% | -462.4% | -343.8% | -246.5% | -185.3% |
| Interest Income | 837K | 20.26M | 57.22M | 38.61M | 22.62M |
| Interest Expense | 2.37M | 106K | 93K | 94K | 0 |
| Other Income / Expenses | (9.66M) | 87.55M | (28.53M) | 12.25M | 1.68M |
| Income Before Tax | (1.84B) | (2.12B) | (892.94M) | (547.51M) | (313.6M) |
| Pre-Tax Margin | -585.7% | -444.1% | -355.1% | -241.1% | -184.3% |
| Income Tax Expense | (1.48M) | (15.03M) | (71K) | (479K) | (837K) |
| Net Income | (1.83B) | (2.1B) | (892.87M) | (547.03M) | (312.76M) |
| Net Margin | -583.1% | -440.6% | -355.1% | -240.9% | -183.8% |
| EPS (Basic) | (53.83) | (50.15) | (18.37) | (10.54) | (5.64) |
| EPS (Diluted) | (55.53) | (50.20) | (18.40) | (10.54) | (5.64) |
| Weighted Avg Shares | 32.95M | 41.93M | 48.53M | 51.89M | 55.46M |
| Weighted Avg Shares (Diluted) | 34.01M | 42M | 48.61M | 51.89M | 55.46M |
Ginkgo Bioworks Holdings, Inc.
NYSE:DNA
Intrinsic Alpha fair value
Locked
Current Price
$8.44
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.